Name: A 2011 Risk: Benefit Analysis of the Anthrax Vaccine Immunization Program (en Inglés)
Price: 428.41 MXN
Availability: InStock
Author: Penny Hill Press Inc ; U. S. Army Command and General Staff Col
ISBN: 9781523312368

Envío gratis

portada A 2011 Risk: Benefit Analysis of the Anthrax Vaccine Immunization Program (en Inglés)

Formato

Libro Físico

Autor

U. S. Army Command and General Staff Col

Ilustrado por

Penny Hill Press Inc

Editorial

Createspace Independent Publishing Platform

Idioma

Inglés

N° páginas

Encuadernación

Tapa Blanda

Dimensiones

28.0 x 21.6 x 0.5 cm

Peso

0.23 kg.

ISBN13

9781523312368

Categorías

Sistemas y servicios de la salud
Enfermedades infectocontagiosas
Medicina popular y salud

A 2011 Risk: Benefit Analysis of the Anthrax Vaccine Immunization Program (en Inglés)

U. S. Army Command and General Staff Col (Autor) · Penny Hill Press Inc (Ilustrado por) · Createspace Independent Publishing Platform · Tapa Blanda

Libro Nuevo

$ 428.41

$ 714.02

Ahorras: $ 285.61

40% descuento

Envío normal

Origen: Estados Unidos (Costos de importación incluídos en el precio)

Se enviará desde nuestra bodega entre el Lunes 15 de Julio y el Martes 23 de Julio.

Lo recibirás en cualquier lugar de México entre 1 y 3 días hábiles luego del envío.

Reseña del libro "A 2011 Risk: Benefit Analysis of the Anthrax Vaccine Immunization Program (en Inglés)"

Safety, efficacy, and legal concerns surrounded the Department of Defense (DoD) Anthrax Vaccine Immunization Program (AVIP) in the early and mid-2000s. Production capacity, patient refusals, and legal injunctions limited vaccine delivery during this time period. Since 2007, the Anthrax Vaccine Adsorbed (AVA) has been administered to all service members deploying to high-risk areas except those medically or administratively exempt. This book evaluates the current AVIP in terms of associated risks and benefits. Aggregate data from long-term studies and review by multiple scientific organizations, both within and external to the DoD, suggest that the AVA is both safe and efficacious. The DoD has tailored the current AVIP policy to protect forces with anticipated high exposure risk. This tailored vaccination policy minimizes vaccine-associated risk for individuals and for the force. Current AVIP benefits for individuals and for force protection outweigh the risks. As risks and benefits change over time, ongoing assessment is essential to ensure that individual and force health promotion are optimized. Continuing long-term scientific safety and efficacy research, ongoing educational efforts, and recognition of patient concerns are essential for the continued success of the AVIP and other force protection programs.